Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc Aims To Market Malaria Vaccine-Reuters


Monday, 7 Oct 2013 07:01pm EDT 

Reuters reported that Glaxosmithkline Plc will seek marketing approval for the malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children. The vaccine known as RTS,S was found, after 18 months of follow-up, to have almost halved the number of malaria cases in young children in the trial, and to have reduced by around a quarter the number of malaria cases in infants. It added that the United Nations health agency, the Geneva-based World Health Organization (WHO), has indicated it may recommend use of the RTS,S vaccine from as early as 2015 if EMA drugs regulators back its licence application. Malaria, a mosquito-borne parasitic disease, kills hundreds of thousands of people a year, mainly babies in the poorest parts of sub-Saharan Africa, and scientists say an effective vaccine is key to attempts to eradicate it. GSK is developing RTS,S with the non-profit PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill & Melinda Gates Foundation to MVI. Previous data sets released from earlier parts of the trial showed the vaccine's efficacy was 65% in babies analysed six months after vaccination, and only around 50% in five to 17 month-olds. And further data released earlier this year found RTS,S's effectiveness wanes over time, with the shot protecting only 16.8% of children over four years. If approved, the vaccine is unlikely to be anything other than neutral for GSK's bottom line. 

Company Quote

48.52
-1.56 -3.12%
25 Jul 2014